ImmunityBio
IBRX
IBRX
62 hedge funds and large institutions have $43.5M invested in ImmunityBio in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 22 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
62
Holders Change
-1
Holders Change %
-1.59%
% of All Funds
1.42%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
8
Increased
21
Reduced
22
Closed
9
Calls
$117K
Puts
$14K
Net Calls
+$103K
Net Calls Change
+$179K
Top Buyers
| 1 |
1
Millennium Management
New York
|
$610K |
| 2 |
VIA
2
Vident Investment Advisory
Alpharetta,
Georgia
|
$1.45M |
| 3 |
3
Morgan Stanley
New York
|
$767K |
| 4 |
4
Renaissance Technologies
New York
|
$1.18M |
| 5 |
VF
5
Virtu Financial
New York
|
$180K |
Top Sellers
| 1 |
1
Fidelity Investments
Boston,
Massachusetts
|
$896K |
| 2 |
AG
2
Artal Group
Luxembourg
|
$0 |
| 3 |
WCM
3
Wildcat Capital Management
New York
|
$2.17M |
| 4 |
4
Vanguard Group
Malvern,
Pennsylvania
|
$6.46M |
| 5 |
5
BlackRock
New York
|
$10.1M |
